Biogen will continue to manufacture oral solid dose products for Eisai, in addition to parenteral products
Eisai has agreed to transfer ownership of its Research Triangle Park-based manufacturing facility in North Carolina, to Biogen.
The agreement expands a manufacturing alliance between the two companies concerning the North Carolina plant entered into in December 2012. Under this latest agreement, Eisai will transfer to Biogen the entire North Carolina plant, including the oral solid dose (OSD) facility, which was formerly leased by Biogen.
Biogen will continue to manufacture OSD products for Eisai after the expiration of the lease, in addition to parenteral products.
Approximately 100 Eisai employees will be offered jobs with Biogen when the deal closes in the second quarter.
After the transfer of manufacturing operations to Biogen, Eisai will continue to base supply chain management services in the Research Triangle Park area. In addition to maintaining global contract manufacturing management and quality assurance in North Carolina, production at the Baltimore plant in Maryland will continue unchanged to supply products for the US, as well as the global market.